A transdermal pharmaceutical composition comprising, vardenafil as a phosphodiesterase type 5 (PDE-5) inhibitor or a pharmaceutically acceptable salt thereof, an enhancer selected from the group consisting of cocamidopropyl betaine, sodium lauroamfoacetate, quaternium 60, isostearamidopropyl morpholine lactate, dipropylene glycol and a combination thereof； and a pharmaceutically acceptable excipient； where: in the case that the enhancer is cocamidopropyl betaine, then vardenafil and the enhancer are present in the transdermal pharmaceutical composition in a weight ratio of 5: 1； in the case that the enhancer is a one-to-one mixture of cocamidopropyl betaine and sodium lauroamphoac etate, vardenafil and the enhancer are present in the transdermal pharmaceutical composition in a 6: 1 weight ratio； in the case that the enhancer is a mixture of cocamidopropyl betaine, sodium lauroamphoacetate and quater-Nium-60, then vardenafil and the enhancer are present in the transdermal pharmaceutical composition in a weight ratio of 4: 1； and in the case that the enhancer is a mixture of cocamidopropyl betaine, sodium lauroamphoacetate, quaternium 60, isostearamidopropyl morpholine lactate and dipropylene glycol, then vardenafil and the enhancer are present in the transdermal pharmaceutical composition at a weight ratio of 3: 1 .Una composición farmacéutica transdérmica que comprende, vardenafilo como inhibidor de la fosfodiesterasa tipo 5 (PDE-5) o una sal farmacéuticamente aceptable del mismo, un potenciador seleccionado del grupo que consiste en cocamidopropil betaína, lauroamfoacetato de sodio, cuaternio 60, isostearamidopropyl morpholine lactate, dipropilenglicol y una combinación de los mismos； y un excipiente farmacéuticamente aceptable； donde: en el caso de que el potenciador sea cocamidopropil betaína, entonces vardenafilo y el potenciador están presentes en la composición farmacéutica transdérmica en un ratio de peso de 5:1； en el caso de que el potenciador sea una mezcl
